CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors

Background: Homologous recombination deficiency (HRD) is a common molecular characteristic of genomic instability, and has been proven to be a biomarker for target therapy. However, until now, no research has explored the changes in the transcriptomics landscape of HRD tumors. Methods: The HRD score...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhiwen, Shen, Jianfeng, Qiu, Junjun, Zhao, Qingguo, Hua, Keqin, Wang, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210593/
https://www.ncbi.nlm.nih.gov/pubmed/34158843
http://dx.doi.org/10.7150/thno.59056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210593/
https://www.ncbi.nlm.nih.gov/pubmed/34158843
http://dx.doi.org/10.7150/thno.59056

Ejemplares similares